Osteogenic Growth Peptide (OGP)
Overview
Osteogenic Growth Peptide is a naturally occurring 14-amino acid peptide identified in serum that promotes osteoblast proliferation and differentiation. The peptide activates the MAP kinase signaling pathway and stimulates collagen synthesis in bone-forming cells. OGP also demonstrates hematopoietic activity, influencing stem cell differentiation in the bone marrow microenvironment. Synthetic analogs have been developed to enhance stability and receptor affinity for potential therapeutic applications in osteoporosis and fracture healing.
Key Research Findings
Preclinical studies in ovariectomized rats and other animal models have demonstrated increased bone formation, trabecular connectivity, and bone strength following OGP administration. In vitro experiments confirm dose-dependent stimulation of osteoblast proliferation and alkaline phosphatase activity. No clinical trials in humans have been published, and the peptide remains in preclinical development with ongoing research into optimized delivery systems and dosing regimens.
Subcutaneous injection
Research Phase
Interested in Osteogenic Growth Peptide (OGP)?
Find a verified provider experienced with Osteogenic Growth Peptide (OGP) protocols in your area. All providers are credentialed and use compliant sourcing.
Find a Osteogenic Growth Peptide (OGP) ProviderRelated Peptides
Teriparatide (Forteo)
FDA ApprovedA recombinant form of the first 34 amino acids of human parathyroid hormone (PTH 1-34). When administered intermittently via daily subcutaneous injection, teriparatide stimulates osteoblastic bone formation more than osteoclastic resorption, producing a net anabolic effect on bone. It activates the PTH1 receptor on osteoblasts, increasing Wnt signaling, osteoblast differentiation, and survival while reducing sclerostin expression.
Abaloparatide (Tymlos)
FDA ApprovedA synthetic 34-amino acid peptide analog of parathyroid hormone-related protein (PTHrP 1-34) that selectively activates the RG conformation of the PTH1 receptor. This receptor selectivity produces a more transient signaling response compared to teriparatide, favoring anabolic bone formation with less stimulation of bone resorption and calcium mobilization. Abaloparatide increases bone mineral density at both cortical and trabecular sites.
Calcitonin
FDA ApprovedA 32-amino acid peptide hormone naturally produced by parafollicular C-cells of the thyroid gland. Calcitonin inhibits osteoclast-mediated bone resorption by binding to calcitonin receptors on osteoclasts, reducing their activity and number. Salmon calcitonin is approximately 40-50 times more potent than human calcitonin and has a longer half-life, making it the preferred therapeutic form.
Vosoritide (Voxzogo)
FDA ApprovedA C-type natriuretic peptide (CNP) analog that acts as an agonist at the natriuretic peptide receptor B (NPR-B) on growth plate chondrocytes. Vosoritide counteracts the constitutively activated FGFR3 signaling that suppresses endochondral ossification in achondroplasia. By stimulating the NPR-B/cGMP/MAPK pathway, it antagonizes the growth-inhibitory FGFR3 signal and restores more normal linear bone growth.